Literature DB >> 4024395

Simultaneous determination of six tumor markers in patients with prostatic carcinoma and bladder tumors.

B Schwemmer, W Schütz, R M Kuntz, A Lehmer.   

Abstract

Serum levels of fucosyltransferase (FT), phosphohexoseisomerase (PHI), tissue polypeptide antigen (TPA), Tennessee antigen (TAG), carcinoembryonic antigen (CEA) and prostatic acid phosphate (PAP) were determined in 75 healthy individuals and in 86 patients with prostatic carcinoma and 38 patients with bladder tumors. The discrimination capacities of the different markers were compared by using inverse distribution plots. At a rate of 5% false positive values the sensitivities for bladder tumors were: FT 30%, TPA 24%, CEA 16%, TAG 15%. The sensitivities for prostatic carcinoma were: PAP 63%, PHI 36%, TPA 18%, CEA 14%, TAG 14%.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4024395     DOI: 10.1007/bf00256074

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  10 in total

1.  Evaluation of biological markers in bladder cancer.

Authors:  Z Wajsman; C E Merrin; T M Chu; R H Moore; G P Murphy
Journal:  J Urol       Date:  1975-12       Impact factor: 7.450

2.  Levels of two plasma fucosyltransferases as an index of disease status in acute myelogenous leukemias.

Authors:  D Kessel; P Khilanani; T H Chou
Journal:  Cancer Treat Rep       Date:  1978-01

3.  Carcinoembryonic antigen in serum, urine and cells of patients with bladder carcinoma.

Authors:  B Wahren; F Edsmyr
Journal:  Urol Res       Date:  1978

4.  Selective inhibition of a plasma fucosyltransferase by N-ethylmaleimide.

Authors:  T H Chou; C Murphy; D Kessel
Journal:  Biochem Biophys Res Commun       Date:  1977-02-07       Impact factor: 3.575

5.  Glycosyltransferases and glycosidases in Morris hepatomas.

Authors:  C H Bauer; P Vischer; H Grünholz; W Reutter
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

6.  Significance of plasma tissue polypeptide antigen determination for diagnosis and follow-up of urothelial bladder cancer.

Authors:  H D Adolphs; P Oehr
Journal:  Urol Res       Date:  1984

7.  Tissue polypeptide antigen (TPA) and prostatic acid phosphatase in serum of prostatic cancer patients.

Authors:  P R Huber; M Rist; F Hering; C Biedermann; G Rutishauser
Journal:  Urol Res       Date:  1983

8.  Serum phosphohexose isomerase in cancer. II. As an index of tumor growth in metastatic carcinoma of the breast.

Authors:  O BODANSKY
Journal:  Cancer       Date:  1954-11       Impact factor: 6.860

9.  Fucosyltransferase activity in metastasizing and nonmetastasizing rat mammary carcinomas.

Authors:  S K Chatterjee; U Kim
Journal:  J Natl Cancer Inst       Date:  1978-07       Impact factor: 13.506

10.  The Tennessee antigen test. An evaluation in cancer and non-cancer patients and normal subjects.

Authors:  C R Pentycross
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

  10 in total
  2 in total

1.  Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tract.

Authors:  A van der Gaast; W J Kirkels; B G Blijenberg; T A Splinter
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Serum tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.

Authors:  A Marczyńska; J Kulpa; J Leńko; M Augustyn
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.